Abstract
White matter (WM) alterations are commonly found across different stages of Alzheimer’s disease (AD). However, the association between these changes with underlying AD pathology such as amyloid-β (Aβ) and tau deposition is still poorly understood. Hitherto, most studies have assessed WM alterations in AD using diffusion tensor imaging (DTI). Nonetheless, DTI has methodological shortcomings that limit an accurate biological interpretation. To address this limitation, here we applied fixel-based analysis (FBA) to disentangle microscopic differences in fiber density (FD) from macroscopic morphological changes in fiber cross-section (FC) in early stages of AD. We further investigated the associations of FBA metrics with AD pathology and cognitive performance. Additionally, we compared FBA results with other commonly used WM metrics derived from DTI, free-water corrected (FW)-DTI and diffusion kurtosis imaging (DKI). To achieve these goals, we included 224 Aβ-negative and 91 Aβ-positive cognitively unimpaired individuals as well as 78 Aβ-positive patients with mild cognitive impairment (MCI) with diffusion-weighted MRI (dMRI), Aβ-PET and tau-PET scans from the Swedish BioFINDER-2 study. We found that tau-PET uptake in medial temporal regions was associated with macrostructural alterations reflected by reduced FC mainly in the parahippocampal part of the cingulum bundle in Aβ-positive individuals. This tau-related WM alteration was also associated with impaired memory. Interestingly, only FBA metrics were able to capture the association between tau-PET uptake and white matter degeneration. No association was found between global amyloid load and any dMRI metrics. Compared to both cognitively unimpaired groups, MCI patients showed a decrease in all FBA metrics in the entire cingulum bundle, uncinate fasciculus and anterior thalamic radiations. Metrics derived from DKI, and FW-DTI revealed a similar pattern of alterations whereas the spatial extent of WM abnormalities detected by DTI was more widespread. Altogether, our results indicate that early WM alterations in AD are mainly due to macrostructural changes identified by FBA metrics, being more closely associated with tau than Aβ pathology. These findings suggest that future studies assessing the effects of AD pathology in white matter tracts should consider using FBA metrics.
Competing Interest Statement
O.H has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Genentech, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. All other authors report no conflict of interests.
Funding Statement
The present study was supported by the Swedish Research Council (2022-00775), ERA PerMed (ERAPERMED2021-184), the Knut and Alice Wallenberg foundation (2017-0383), the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s disease) at Lund University, Greta and Johan Kockska Foundation, the Swedish Alzheimer Foundation (AF-980907), the Swedish Brain Foundation (FO2021-0293), The Parkinson foundation of Sweden (1412/22), the Cure Alzheimer’s fund, the Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, the Skåne University Hospital Foundation (2020-O000028), Regionalt Forskningsstöd (2022-1259) and the Swedish federal government under the ALF agreement (2022-Projekt0080).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical Review Board in Lund, Sweden gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Anonymized data will be shared by request from a qualified academic investigator for the sole purpose of replicating procedures and results presented in the article and as long as data transfer is in agreement with EU legislation on the general data protection regulation and decisions by the Ethical Review Board of Sweden and Region Skåne, which should be regulated in a material transfer agreement.
